Using GPT-4o reasoning to transform cancer care

Color Health just rolled out something called Cancer Copilot, and it's a pretty direct bet that GPT-4o can act like a tireless second set of eyes for oncologists. The idea is simple to state but hard to execute: feed the model a patient's records, and have it flag what's missing before a treatment plan gets locked in. A skipped biomarker test. An imaging study that never got ordered. The kind of gap that, in a busy clinic, can slip through and delay care by weeks.

What makes this different from a generic chatbot bolted onto a hospital portal is the workup piece. The tool doesn't just point out a hole in the chart, it drafts a tailored plan for filling it, built around evidence-based screening and treatment guidelines. That's the part OpenAI is leaning on GPT-4o's reasoning for — not just pattern-matching symptoms, but stitching together a coherent next-step recommendation that a physician can actually act on, or push back against.

Color Health isn't new to this space. The company has spent years building infrastructure around genetic testing and virtual cancer care, so this is less a pivot and more an extension of what they already do, now with a language model doing the heavy lifting on diagnostic review. And that matters because cancer care is notoriously fragmented — a patient might see an oncologist, a radiologist, a primary care doctor, and a lab tech, none of whom necessarily has the full picture at the same time. Cancer Copilot is pitched as a way to stitch that picture back together fast enough to matter.

The stakes here are obvious even if the technology is unglamorous. Nobody's claiming GPT-4o diagnoses cancer better than a pathologist. The claim is narrower and, frankly, more believable: that it can catch administrative and clinical gaps humans miss when they're juggling too many charts, and get patients into treatment sooner. In oncology, sooner is not a small word.